Aprea Therapeutics, Inc. (APRE) Stock Price & Growth Analysis

New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out

Aprea Therapeutics, Inc.

APRE

NASDAQ

Unprofitable

EPS improving

Unprofitable

EPS improving

Biotechnology

Next Earning date - 13 May 2025

Biotechnology

Next Earning date - 13 May 2025

1.65USD

0.01 ( 0.84%)

Market Closed (as of May 08, 20:00 EDT)

Relative Strenght

Volume Buzz

-81%

Earning Acce

Dist 52w H.

72%

Overview Chart

Quote Panel

Updated May 9, 2025

1W -5.71 % 1M 6.45 % 3M -54.04 % 1Y -70.48 %

Key Metrics

Market Cap
9.14M
Shares Outstanding
5.53M
Share in Float
4.82M
Dividende
0

Earning Date
13 May 2025
Price Target
1.6538
Average Volume
24696
Beta
1.642

Range
1.412-5.9
Industry
Biotechnology
Website
https://atrinpharma.com
Sector
Healthcare

Fundamentals

N/A

P/E Ratio

9.70x

P/S Ratio

0.51x

P/B Ratio

0.0

Debt/Equity

-1375.5%

Net Margin

$-2.4

EPS

How APRE compares to sector?

P/E Ratio

Fundamentals

Relative Strength

APRE

Sector

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Relative Strength

APRE

Sector

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Forecast

$900K

NaN%

2025-Revenue

$1.77

-262%

2025-EPS

$540K

117%

2025-EBITDA

Analyst rating

Strong Sell

Sell

Buy

Neutral

Strong Buy

Buy

Price Target

NaN(-100.00%)

Number of analyst

Last analyst upgrade/downgrade

Loop Capital Markets

initialise

Previous: Not converted

2023-03-10

Now: Buy

Citigroup

initialise

Previous: Not converted

2023-03-10

Now: Buy

RBC Capital

initialise

Previous: Not converted

2023-03-10

Now: Outperform

Cowen & Co.

initialise

Previous: Not converted

2023-03-10

Now: Market Perform

Forecast

Analyst rating

Last analyst upgrade/downgrade

Earnings Growth

YoY

Current

Estimates

Q1.23

N/A

-1.34
vs -7.20

Q2.23

N/A

-0.87
vs -19.80

Q3.23

N/A

-0.86
vs -2.40

Q4.23

N/A

-0.92
vs -0.92

Q1.24

N/A

-0.67
vs -1.34

Q2.24

N/A

-0.58
vs -0.87

Q3.24

N/A

-0.64
vs -0.86

Q4.24

N/A

-0.49
vs -0.92

Q1.25

N/A

-0.65
vs -0.67

Q2.25

N/A

-0.70
vs -0.58

Sales Growth

YoY

Current

Estimates

Q3.22

NA vs NA

Q4.22

NA vs NA

Q1.23

NA vs NA

Q2.23

249.7K vs NA

Q3.23

319.5K vs NA

Q4.23

14.1K vs NA

Q1.24

380.6K vs NA

Q2.24

+125%

561.6K vs 249.7K

Q3.24

-100%

NA vs 319.5K

Q4.24

-100%

NA vs 14.1K

Return on Equity

QoQ

Q1.23

-16%

-0.16
vs -4.32

Q2.23

-14%

-0.14
vs -0.16

Q3.23

-16%

-0.16
vs -0.14

Q4.23

-19%

-0.19
vs -0.16

Q1.24

-9%

-0.09
vs -0.19

Q2.24

-13%

-0.13
vs -0.09

Q3.24

-17%

-0.17
vs -0.13

Q4.24

-15%

-0.15
vs -0.17

Institutionnal Ownership

QoQ

Q4.22

27
vs 25

Q1.23

2
vs 27

-93%

Q2.23

1
vs 2

-50%

Q3.23

1
vs 1

Q4.23

1
vs 1

Q1.24

2
vs 1

100%

Q2.24

1
vs 2

-50%

Q3.24

1
vs 1

Earnings Growth

Latest News

globenewswire.com

8 hours ago

Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial

globenewswire.com

8 hours ago

Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

globenewswire.com

8 hours ago

Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC)

globenewswire.com

8 hours ago

Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics

globenewswire.com

8 hours ago

Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward

zacks.com

10 hours ago

Here's Why Aprea Therapeutics (APRE) Could be Great Choice for a Bottom Fisher

Company Description

1.65USD

N/A

9.70x

0.51x

0.0

-1375.5%

$-2.4

$900K

$1.77

$540K

Earnings Growth

Latest News

$900K

$1.77

$540K

Company Description

1.65USD

N/A

9.70x

0.51x

0.0

-1375.5%

$-2.4